nivolumab,relatlimab
bms
['nivo', 'biomarker']
so we are now going to spend the next ascos an esmos discussing nivo+ipi vs nivo+lag3 and the diff in tox- management has improved, so check for the nivo mono for ref pls- and patient selection (the biomarker holy grail story) and sequencing. this hurts patients. #asco2022
#Melanoma patient advocate, MD/PhD, in want of patient-centred research. Member of the first EU Cancer Mission Board. Views are totally my own.